Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay

NCT02688491 is registered in ClinicalTrials.gov with First Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT02688491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02688491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Phase
Not applicable
Overall status
Unknown status
Start date
July 31, 2016
Completion date
July 31, 2026
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal neoplasms, targeted molecular therapy